Securities code: 002422 securities abbreviation: Sichuan Kelun Pharmaceutical Co.Ltd(002422) Announcement No.: 2022-009 Sichuan Kelun Pharmaceutical Co.Ltd(002422)
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Sichuan Kelun Pharmaceutical Co.Ltd(002422) (hereinafter referred to as the "company") recently received the reply on approving Sichuan Kelun Pharmaceutical Co.Ltd(002422) public issuance of convertible corporate bonds (zjxk [2022] No. 255) issued by China Securities Regulatory Commission (hereinafter referred to as the "CSRC"). The specific reply contents are as follows:
1、 The company is approved to issue convertible corporate bonds with a total face value of 3 billion yuan to the public for a period of 6 years. 2、 The issuance of convertible corporate bonds shall be implemented in strict accordance with the prospectus and issuance announcement submitted by the company to the CSRC.
3、 This reply shall be valid within 12 months from the date of approval of issuance.
4、 From the date of approval of the issuance to the end of the issuance of convertible corporate bonds, if the company has major events, it shall timely report to the CSRC and deal with them in accordance with relevant regulations.
The board of directors of the company will, in accordance with the requirements of relevant laws and regulations and the above approval documents, choose an opportunity to handle matters related to the public issuance of convertible corporate bonds within the scope of authorization of the general meeting of shareholders, and timely perform the obligation of information disclosure. Please invest rationally and pay attention to investment risks.
It is hereby announced.
Sichuan Kelun Pharmaceutical Co.Ltd(002422) board of directors February 10, 2022
